Israel's Entera Bio Q3 net loss widens
Entera Bio reported a Q3 2025 net loss of $3.2 million, with increased operating expenses. Cash reserves are expected to support operations through mid-2026. Research and development expenses rose slightly to $1.6 million. The sole analyst rating is "buy," with a median 12-month price target of $10.00, significantly above the current price of $2.74.
)
Overview
- Entera Bio reports Q3 2025 net loss of $3.2 mln, with increased operating expenses
Outlook
- Cash reserves expected to support operations through mid-2026
Result Drivers
- Research and development expenses were $1.6 million for the three months ended September 30, 2025, compared to $1.5 million for the same period in 2024, an increase of $0.1 million.
Key Details
Metric Beat/Mis Actual Consensu
s s
Estimate
Q3 Net -$3.20
Income mln
Q3 $3.30
Operatin mln
g
Expenses
Analyst Coverage
- The one available analyst rating on the shares is “buy”
- The average consensus recommendation for the biotechnology & medical research peer group is “buy”
- Wall Street’s median 12-month price target for Entera Bio Ltd is $10.00, about 72.6% above its November 13 closing price of $2.74
Press Release: For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact . (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
